Reduction of methane emissions from manure

An investigation is made of potential CH4 emission reduction options evaluated in the context of NH3 and N2O emissions

Quick scan van be- en verwerkingstechnieken voor dierlijke mest

In opdracht van het Ministerie van LNV is door het Praktijkonderzoek van de Animal Sciences Group en door Agrotechnology & Food Innovations een 'quick scan' uitgevoerd naar be- en verwerkingstechnieken voor dierlijk mest. Hiermee moest duidelijk worden in welke mate dergelijke technieken kunnen bijdragen aan een terugdringing van het mineralenoverschot dat verwacht wordt wanneer in 2006 een nieuw mest- en mineralenbeleid van kracht wordt. De uitgevoerde 'quick scan' geeft een beschrijving van 18 technieken voor mestbe- en verwerking (incl. processchema) en analyseert deze aan de hand van de stand van de techniek, afzetmarkt, schaalgrootte, mestsoort, productkwaliteit en -kwantiteit, kosten en emissies. Tevens wordt vermeld welke initiatieven of bedrijven zich met de betreffende technieken bezighoude

Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1%

Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with re-spect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin. Copyright (C) 2012 S. Karger AG, Base

Blood coagulation and beyond: position paper from the fourth Maastricht consensus conference on thrombosis

The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The "coagulome" as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, and kidney. Four investigators shared their views on these organ- specific topics. Theme 2: Novel mechanisms of thrombosis. Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infection-associated coagulopathies perturb the hemostatic balance resulting in thrombosis and/ or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies. This theme included state-of- the- art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models. Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularized organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation-associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management. Plenary presentations addressed controversial areas, i. e., thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies, and clinically tested factor XI(a) inhibitors, both possibly with reduced bleeding risk. Finally, COVID- 19-associated coagulopathy is revisited.Nephrolog

Scheiding van vergiste varkensdrijfmest

Op een proefinstallatie voor de verwerking van varkensdrijfmest zijn een aantal apparaten getest op hun mogelijkheden om vergiste varkensdrijfmest te scheiden in een vaste en een vloeistoffractie. De proeven werden uitgevoerd met 2 zeefbandpersen, 4 decanteercentrifuges en 3 andersoortige perse